Eli Lilly's (LLY) sofetabart mipitecan receives US FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer

Eli Lilly's receipt of Breakthrough Therapy designation for its drug sofetabart mipitecan is a significant milestone, indicating accelerated development and potential market exclusivity in treating platinum-resistant ovarian cancer.

Newsquawk StaffPublished On the live feed at 7 more headlines followed before this page went public
Newsquawk headlinesUTC

Around 2 borrowers are looking to sell new US investment-grade notes on Tuesday, according too Bloomberg's daily survey

Amazon (AMZN) CEO Jassy says seeing some sellers passing along tariffs and others absorbing it; in the next couple of years, could see them having fewer people than they had before - CNBC

Eli Lilly's (LLY) sofetabart mipitecan receives US FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer

EU set to approve Universal Music's (UMG) downtown buy

NBP said to to approve plan to increase gold holdings to 700 tonnes

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This designation often leads to increased investor confidence and can drive the stock's performance positively, particularly in the biotech sector, which is sensitive to regulatory news. Watch for market reactions around competitor products and overall sentiment in health care stocks.

Related headlines

The whole workspace, free to try.

Try it free